Background Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP
synthase, has been associated with accelerated sputum-culture conversion in patients with …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial (…

To halt the global tuberculosis epidemic, transmission must be stopped to prevent new
infections and new cases. Identification of individuals with tuberculosis and prompt initiation of …

Background Sputum culture conversion is often used as an early microbiological endpoint in
phase 2 clinical trials of tuberculosis treatment on the basis of its assumed predictive value …

Background. Resistance to second-line drugs develops during treatment of multidrug-resistant
(MDR) tuberculosis, but the impact on treatment outcome has not been determined. …

Infectious diseases are a global health problem affecting billions of people. Developing
rapid and sensitive diagnostic tools is key for successful patient management and curbing …

Background During the ongoing coronavirus disease 2019 (COVID-19) pandemic, many
individuals were infected with and have cleared the virus, developing virus-specific antibodies …

Background Effector CD4 T cells represent a key component of the host’s anti-tuberculosis
immune defense. Successful differentiation and functioning of effector lymphocytes protects …

The development of variant Creutzfeldt-Jakob disease (vCJD) in three recipients of non-leukoreduced
red blood cells from asymptomatic donors who subsequently developed the …

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB),
has had limited use outside clinical trials. We present the early treatment results for 53 …